LIB Therapeutics

LIB Therapeutics is a clinical-stage biopharmaceutical company dedicated to providing novel, effective, safe, and convenient injectable and oral PCSK9 inhibitors for millions of patients with cardiovascular disease (CVD) or very high or high risk of CVD. These patients require substantial additional reductions in LDL-C despite maximum tolerated doses of statins and other oral lipid-lowering agents.